Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.

devices, tools, and enabling technologies”, but will look at investments more broadly across healthcare. Aberman was at Regeneron for seven years, rising to the role of senior vice president of ...

It provides a range of software, services, and devices for ... decision regarding the Eylea biosimilar case as a modest setback but believes it does not overshadow Regeneron’s long-term growth ...

Boston Scientific makes surgical devices and medical equipment to treat ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies, inflammation ...

Welcome to the Winter 2025 issue of “FCA Enforcement & Compliance Digest,” our quarterly newsletter in which we compile essential updates on ...

The sum-of-the-parts way and the platform way. Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent. Eylea is a VEGF drug that is injected into ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...